Autoimmune Liver Disease — Viva Defence

Long Case Viva Defence

The scenario

A 54-year-old woman presents with a 12-month history of progressive fatigue and pruritus, and a 3-month history of painless jaundice. She has hypothyroidism but no other past history. Blood tests show ALP 520 U/L, gamma-GT 390 U/L, bilirubin 75 micromol/L, ALT 180 U/L, albumin 33 g/L, IgM 4.8 g/L (raised), IgG 28 g/L (raised, upper limit 16). AMA positive at 1:640, ANA positive at 1:5120, SMA positive at 1:160, anti-LKM1 negative. IgG4 normal. Liver biopsy shows a florid duct lesion AND interface hepatitis with a plasma-cell infiltrate. Ultrasound shows normal biliary ducts. FibroScan 14 kPa (consistent with cirrhosis). [1]

Opening statement (SASPOP)

"This is Mrs K, a 54-year-old woman presenting with a 12-month history of fatigue and pruritus and a 3-month history of jaundice, found to have an AIH-PBC overlap syndrome — she meets the Paris criteria for both diseases, with a cholestatic LFT pattern, a positive AMA, a raised IgM and a florid duct lesion for PBC, plus a hepatocellular component, a raised IgG, positive ANA and SMA, and interface hepatitis with a plasma-cell infiltrate for AIH. Her FibroScan of 14 kPa indicates established cirrhosis. Her main problems are the overlap syndrome, which needs a combined UDCA and immunosuppressive strategy; the cirrhosis with its surveillance requirements; the pruritus; the osteoporosis risk from both the cholestasis and the corticosteroids I will use; and the psychosocial impact of a complex chronic diagnosis. My priorities are to start ursodeoxycholic acid for the PBC component, check the TPMT activity and then start prednisolone plus azathioprine for the AIH component, stage and surveil the cirrhosis, manage the pruritus and the bone health, and involve a multidisciplinary team including hepatology, dietetics and the GP." [1]

Problem list (numbered, prioritised)

1. AIH-PBC overlap syndrome — the central problem; needs combined UDCA and immunosuppression.
2. Cirrhosis (FibroScan 14 kPa) — requires variceal and HCC surveillance.
3. Pruritus — a major quality-of-life issue.
4. Osteoporosis risk — from cholestasis and corticosteroids.
5. Fat-soluble vitamin deficiency — likely given the cholestasis and jaundice.
6. Hypothyroidism — a common associated autoimmune condition; ensure it is well replaced.
7. Psychosocial impact and communication — complex chronic diagnosis, lifelong therapy. [1]

Integrated management plan

Pillar 1 — Ursodeoxycholic acid for the PBC component: "I would start UDCA at 13 to 15 mg/kg/day in divided doses, first-line for all stages of PBC. The 1994 Lindor NEJM trial showed it slows histological progression and reduces the need for transplant [2]. This is lifelong therapy."

Pillar 2 — Immunosuppression for the AIH component: "I would add prednisolone 0.5 to 1 mg/kg/day plus azathioprine 1 to 2 mg/kg/day. Critically, I would check the thiopurine methyltransferase (TPMT) activity BEFORE starting azathioprine, because TPMT deficiency causes fatal myelosuppression [5]. I would monitor the full blood count weekly for the first month, then monthly. Because she has established cirrhosis, I would use prednisolone rather than budesonide — budesonide is ineffective in cirrhosis because of portosystemic shunting."

Pillar 3 — Cirrhosis surveillance: "FibroScan confirms cirrhosis. I would arrange an upper GI endoscopy for variceal surveillance, six-monthly ultrasound plus alpha-fetoprotein for hepatocellular carcinoma, and a DEXA for bone density. I would check the fat-soluble vitamin levels and replace as needed." [1]

Pillar 4 — Symptom control: "For the pruritus, I would start cholestyramine, given separately from UDCA by at least 2 to 4 hours. If inadequate, add rifampicin 150 to 300 mg twice daily with liver function monitoring, then naltrexone or sertraline. For the fatigue, there is no specific therapy — I would exclude anaemia, hypothyroidism and vitamin D deficiency, and address sleep, mood and deconditioning." [1]

Pillar 5 — Bone and nutritional health: "Calcium and vitamin D supplementation, and a bisphosphonate if the DEXA shows osteoporosis. Steroid-sparing measures: monitor blood glucose and blood pressure, and consider an early switch to azathioprine monotherapy as the prednisolone is tapered." [1]

Pillar 6 — Second-line and transplant: "If her biochemistry does not normalise, I would consider adding obeticholic acid — but ONLY if her cirrhosis is compensated (Child-Pugh A). OCA is contraindicated in decompensated cirrhosis because it can precipitate liver failure [3]. If she develops decompensation (ascites, encephalopathy, variceal bleed, rising bilirubin), I would refer for liver transplant assessment."

Probing questions the examiner would ask

Q: How do you apply the Paris criteria for AIH-PBC overlap in this patient? [1]

A: "The Paris criteria require two of three AIH features AND two of three PBC features. For AIH: interface hepatitis; ALT two to five times the upper limit; IgG two times the upper limit OR positive ANA/SMA. She meets all three — interface hepatitis on biopsy, an ALT of 180 (above the upper limit, though at the lower bound), a raised IgG, and positive ANA and SMA. For PBC: AMA positive; compatible biopsy (florid duct lesion); raised IgM. She meets all three — AMA positive, florid duct lesion, raised IgM. So she has definite overlap. The IAIHG position statement (Boberg 2011) cautions that overlap is partly a research concept and patients should be treated for their predominant feature, but here both diseases are clearly active and a combined strategy is justified [7]."

Q: Why did you check the IgG4, and what would a raised IgG4 have meant? [1]

A: "I checked the IgG4 to exclude IgG4-related sclerosing cholangitis, the steroid-responsive mimic of PSC. A raised IgG4 in a cholestatic patient, especially an older man with a strictured cholangiogram and autoimmune pancreatitis, would indicate IgG4-sclerosing cholangitis, whose treatment is systemic corticosteroids — the opposite of PSC, which is not steroid-responsive. In this patient the normal IgG4 and the classic PBC features (AMA, raised IgM, florid duct lesion) make IgG4-disease unlikely, but the check is part of the standard cholestatic workup." [1]

Q: Why are you using prednisolone rather than budesonide for the AIH component? [1]

A: "Budesonide is a first-pass corticosteroid that achieves high hepatic concentrations with minimal systemic exposure, making it an attractive steroid-sparing option in non-cirrhotic AIH. However, in cirrhosis the portosystemic shunting bypasses the first-pass metabolism, so budesonide behaves like systemic prednisolone without the steroid-sparing benefit — and it is contraindicated in cirrhosis. This patient has established cirrhosis on FibroScan, so prednisolone is the correct choice, with diligent attention to bone density, blood glucose and blood pressure." [1]

Q: What is the role of obeticholic acid in this patient, and what are the cautions? [1]

A: "OCA is a farnesoid X receptor agonist, shown in the 2016 POISE trial to improve the composite of ALP and bilirubin in patients with an inadequate response to UDCA [3]. In this patient, if her PBC biochemistry does not respond to UDCA plus immunosuppression, I would consider adding OCA — but only if her cirrhosis is compensated (Child-Pugh A). OCA is contraindicated in decompensated (Child-Pugh B and C) cirrhosis because it can precipitate liver failure and death. It also commonly worsens pruritus, which is the commonest reason to reduce the dose or stop the drug. The dose is 5 mg daily for six months, then 10 mg daily if the target is not met, with dose reduction to once weekly in stage 4 compensated cirrhosis."

Q: What surveillance does she need for her cirrhosis? [1]

A: "Upper GI endoscopy for variceal surveillance at diagnosis and every one to three years depending on findings; six-monthly ultrasound plus alpha-fetoprotein for hepatocellular carcinoma; a baseline and biennial DEXA for osteoporosis; and annual fat-soluble vitamin levels (A, D, E, K) given her cholestasis. If she develops any feature of decompensation — ascites, encephalopathy, variceal bleed, a rising bilirubin — I would refer her for liver transplant assessment." [1]

Q: How would her management change if she wanted to become pregnant? [1]

A: "I would plan pregnancy for when the disease is in biochemical remission. UDCA is safe in pregnancy and should be continued. Prednisolone and azathioprine are considered compatible with pregnancy and should be continued. Mycophenolate mofetil (if she were on it) is teratogenic and must be stopped at least six weeks before conception. I would counsel that there is a risk of a disease flare in the postpartum period (within three to six months), so I would monitor her closely then. The cirrhosis complicates pregnancy and I would involve a maternal-fetal medicine specialist and a hepatologist in a joint clinic." [1]

Communication and shared decision-making

"I would explain the diagnosis in plain language — that her immune system is attacking both the bile ducts and the liver cells, which is why she has features of two diseases, and the treatment needs to address both. I would explain that the UDCA is for the bile duct disease (lifelong), and the prednisolone and azathioprine are for the immune attack on the liver cells (at least 24 months before we consider withdrawal). I would be honest about the chronicity, the surveillance burden, the corticosteroid side effects, and the transplant possibility if the disease progresses. I would involve the GP, the dietitian, the physiotherapist, and a hepatology nurse specialist. I would document the shared decisions and review them as the biochemistry responds." [1]

Short Case Discussion — Abdominal Examination of Chronic Cholestasis

Instruction: "Examine this patient's abdomen and comment on the relevant general signs." [1]

Systematic examination routine

1. End of bed — observe for jaundice, excoriations (from scratching), hyperpigmentation, muscle wasting, spider naevi, parotid enlargement, and the characteristic xanthelasma (yellow periorbital deposits) and xanthomata of chronic cholestasis.
2. Hands and arms — clubbing (in advanced chronic liver disease), palmar erythema, Dupuytren contracture, leukonychia, and a liver flap if there is encephalopathy.
3. Face and chest — icteric sclerae, xanthelasma around the eyes, spider naevi in the superior vena cava distribution, loss of axillary and pubic hair, gynaecomastia.
4. Abdomen — inspect for distension (ascites), caput medusae, surgical scars; palpate for hepatomegaly, splenomegaly (portal hypertension), and the character of the liver edge (firm and irregular in cirrhosis); percuss for shifting dullness (ascites); and auscultate for a bruit (HCC, renal artery stenosis).
5. Complete the examination — examine for the stigmata of associated autoimmune disease (thyromegaly for autoimmune thyroid disease, dry eyes and mouth for Sjogren, joint deformity for rheumatoid arthritis, a rash for dermatomyositis or psoriasis). [1]

Key physical signs the patient demonstrates (for this case)

• Icteric sclerae and jaundice
• Excoriations and prurigo nodularis (from scratching)
• Hyperpigmentation (melanin deposition in chronic cholestasis)
• Xanthelasma around the eyes (a key discriminator for chronic cholestasis, particularly PBC)
• Palmar erythema and a few spider naevi (from the cirrhosis)
• A firm, smooth liver edge palpable 3 cm below the costal margin
• Splenomegaly (portal hypertension from the cirrhosis)
• No ascites [1]

Presentation template

"I examined Mrs K, a 54-year-old woman who is icteric at the end of the bed, with excoriations on her forearms and legs consistent with pruritus, hyperpigmentation, and yellow periorbital deposits consistent with xanthelasma. The hands show palmar erythema and no clubbing. The face shows icteric sclerae and bilateral xanthelasma. There are a few spider naevi in the superior vena cava distribution but no parotid enlargement or gynaecomastia. The abdomen reveals a firm, smooth liver edge palpable 3 cm below the costal margin, and a palpable spleen tip. There is no ascites. These findings — the chronic cholestatic stigmata of xanthelasma and excoriations, with hepatosplenomegaly — are consistent with a chronic cholestatic liver disease such as primary biliary cholangitis, complicated by cirrhosis. I would like to check the antimitochondrial antibody, the immunoglobulins, and arrange an ultrasound and a FibroScan to stage the disease." [1]

Discussion questions

Q: What is the significance of the xanthelasma and the xanthomata? [1]

A: "Xanthelasma (yellow periorbital deposits) and xanthomata (tuberous and tendinous deposits) are a feature of the hypercholesterolaemia of chronic cholestasis, particularly in PBC. The cholesterol is raised because of the impaired biliary excretion. Paradoxically, despite the marked hypercholesterolaemia, patients with PBC do NOT have an increased cardiovascular mortality — the lipid profile is not atherogenic in the way that, say, familial hypercholesterolaemia is. The xanthelasma can be disfiguring and is a marker of chronic cholestasis, but it does not require lipid-lowering therapy specifically for cardiovascular prevention." [1]

Q: How do you distinguish the three autoimmune liver diseases at the bedside? [1]

A: "The bedside signs point to a chronic cholestatic disease (xanthelasma, excoriations, hyperpigmentation, a woman) — which favours PBC. PSC is more often in a younger man with ulcerative colitis, and the bedside signs are similar (chronic cholestasis) but without the female predominance. Autoimmune hepatitis is a hepatocellular disease, so the bedside signs are those of chronic hepatocellular injury and (often) corticosteroid use — striae, moon face, acne, and the stigmata of cirrhosis, but WITHOUT the prominent xanthelasma and cholestatic excoriations. The bedside signs give a pointer, but the diagnosis is made on the LFT pattern, the autoantibody panel, the immunoglobulins, and (where needed) the cholangiogram and the biopsy." [1]

Q: What is the simplified diagnostic score for autoimmune hepatitis, and when do you use it? [1]

A: "The simplified score (Hennes 2008) uses four variables — the autoantibody titre, the IgG level, the histology (interface hepatitis with plasma cells), and the exclusion of viral hepatitis — to give a score that defines probable AIH at six or more and definite AIH at seven or more, with a sensitivity of 88 percent and specificity of 97 percent at the cut-off of six. I use it at the bedside when a patient presents with a hepatocellular LFT pattern and I have the autoantibody and IgG results — it structures the diagnostic reasoning and tells me whether I have enough to start immunosuppression or whether I need a biopsy to confirm [6]."

Q: When would you suspect IgG4-related sclerosing cholangitis, and why does it matter? [1]

A: "I would suspect it in an older man with a cholestatic picture, a strictured cholangiogram (mimicking PSC), a raised serum IgG4, and an association with autoimmune pancreatitis (a 'sausage-shaped' pancreas on imaging). It matters because IgG4-sclerosing cholangitis is HIGHLY steroid-responsive, whereas PSC is NOT — the treatment is opposite. Missing IgG4-disease denies the patient an effective therapy, and misdiagnosing PSC and treating with steroids exposes the patient to harm without benefit. I check a serum IgG4 in every cholestatic patient as part of the standard workup." [1]

Q: How does the presence of cirrhosis change the management of this overlap patient? [1]

A: "Cirrhosis changes three things. First, it rules out budesonide — I must use prednisolone, because budesonide is ineffective in cirrhosis (portosystemic shunting). Second, it rules out or dose-reduces obeticholic acid — OCA is contraindicated in decompensated cirrhosis and dose-reduced in stage 4 compensated cirrhosis. Third, it mandates surveillance — variceal surveillance by endoscopy, hepatocellular carcinoma surveillance by six-monthly ultrasound plus alpha-fetoprotein, and a transplant assessment if she decompensates. The cirrhosis is the reason her management is more complex than a non-cirrhotic overlap patient." [1]